As a consequence, high-affinity EGFR antibodies should exert less stimulatory and therefore less harmful effects on RAS mutant tumor clones than lower-affinity therapeutic antibodies that permit residual RTK-mediated signaling. The gene discussed is EGFR; the disease is neoplasm.